Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EVALUATION OF THE TOLERANCE AND PHARMACOKINETIC PROFILE OF HIGH FAVIPIRAVIR DOSES IN HEALTHY VOLUNTEERS EVALUATION DE LA TOLERANCE ET DU PROFIL PHARMACOCINETIQUE DE DOSES ELEVEES DE FAVIPIRAVIR CHEZ LE VOLONTAIRE SAIN

Next Previous
Trial Profile

EVALUATION OF THE TOLERANCE AND PHARMACOKINETIC PROFILE OF HIGH FAVIPIRAVIR DOSES IN HEALTHY VOLUNTEERS EVALUATION DE LA TOLERANCE ET DU PROFIL PHARMACOCINETIQUE DE DOSES ELEVEES DE FAVIPIRAVIR CHEZ LE VOLONTAIRE SAIN

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Favipiravir (Primary)
  • Indications COVID 2019 infections; Ebola virus infections; Influenza virus infections; Severe fever with thrombocytopenia syndrome
  • Focus Adverse reactions
  • Acronyms FAVIDOSE

    • Most Recent Events

    • 05 Apr 2024 Status changed from not yet recruiting to recruiting.
    • 04 Mar 2024 Planned End Date changed from 1 Jun 2027 to 1 Oct 2027.
    • 04 Mar 2024 Planned primary completion date changed from 1 Jan 2027 to 1 May 2027.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top